Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
Status:
Completed
Trial end date:
2017-03-27
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of SC administrations of
Benralizumab or Placebo in the subjects with Eosinophilic Chronic Rhinosinusitis in a
multicenter, randomized, double-blind, placebo-controlled study. The pharmacokinetics and
immunogenicity will be assessed secondarily.